MY133473A - Haterocyclic glycyl beta-alanine derivatives. - Google Patents
Haterocyclic glycyl beta-alanine derivatives.Info
- Publication number
- MY133473A MY133473A MYPI99001398A MYPI9901398A MY133473A MY 133473 A MY133473 A MY 133473A MY PI99001398 A MYPI99001398 A MY PI99001398A MY PI9901398 A MYPI9901398 A MY PI9901398A MY 133473 A MY133473 A MY 133473A
- Authority
- MY
- Malaysia
- Prior art keywords
- haterocyclic
- glycyl
- beta
- alanine derivatives
- compounds
- Prior art date
Links
- YOKCETMQAPIAGM-UHFFFAOYSA-N 3-[(2-aminoacetyl)amino]propanoic acid Chemical class NCC(=O)NCCC(O)=O YOKCETMQAPIAGM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8139498P | 1998-04-10 | 1998-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY133473A true MY133473A (en) | 2007-11-30 |
Family
ID=22163868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99001398A MY133473A (en) | 1998-04-10 | 1999-04-10 | Haterocyclic glycyl beta-alanine derivatives. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1070060A1 (cs) |
| JP (1) | JP2002511462A (cs) |
| KR (1) | KR20010042614A (cs) |
| CN (1) | CN1304406A (cs) |
| AR (1) | AR015759A1 (cs) |
| AU (1) | AU765294B2 (cs) |
| BR (1) | BR9910119A (cs) |
| CA (1) | CA2326665A1 (cs) |
| CZ (1) | CZ20003672A3 (cs) |
| IL (1) | IL138677A0 (cs) |
| MY (1) | MY133473A (cs) |
| NO (1) | NO20005084L (cs) |
| NZ (1) | NZ507292A (cs) |
| PL (1) | PL343406A1 (cs) |
| RU (1) | RU2215746C2 (cs) |
| TW (1) | TWI247008B (cs) |
| WO (1) | WO1999052896A1 (cs) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| AU2209800A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| AU760174B2 (en) | 1999-02-09 | 2003-05-08 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
| BR0010599A (pt) * | 1999-04-12 | 2002-02-13 | Aventis Pharma Ltd | Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina |
| SK15342001A3 (sk) * | 1999-04-28 | 2002-06-04 | Basf Aktiengesellschaft | Antagonisty integrínového receptora |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| ES2295150T3 (es) | 2000-04-17 | 2008-04-16 | Ucb Pharma, S.A. | Derivados de enamina como moleculas de adhesion celular. |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6720315B2 (en) | 2000-06-15 | 2004-04-13 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives |
| CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| MXPA05006732A (es) * | 2002-12-20 | 2005-09-08 | Pharmacia Corp | El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina. |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| EP2205599B1 (de) | 2007-10-18 | 2012-06-06 | Boehringer Ingelheim International GmbH | Cgrp-antagonisten |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| CA2705599A1 (en) * | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| EP2875021B1 (en) | 2012-07-18 | 2017-08-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| SG11201609050UA (en) | 2014-05-30 | 2016-12-29 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators |
| HK1244806A1 (zh) | 2015-12-30 | 2018-08-17 | Saint Louis University | 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物 |
| KR102515507B1 (ko) * | 2016-11-08 | 2023-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤 아미드 |
| AU2021270095A1 (en) * | 2020-05-14 | 2022-12-22 | Ube Corporation | 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| JPWO2023085396A1 (cs) | 2021-11-12 | 2023-05-19 | ||
| CN115626912B (zh) * | 2022-09-27 | 2024-03-26 | 中山大学 | 一种硫脲化合物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| RU2126001C1 (ru) * | 1995-01-10 | 1999-02-10 | Самдзин Фармасьютикал Ко., Лтд | Производные пиперазина и фармацевтическая композиция на их основе |
| ES2161373T3 (es) * | 1995-08-30 | 2001-12-01 | Searle & Co | Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas. |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| JP2002511052A (ja) * | 1996-08-29 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
-
1999
- 1999-04-09 AU AU34499/99A patent/AU765294B2/en not_active Ceased
- 1999-04-09 CA CA002326665A patent/CA2326665A1/en not_active Abandoned
- 1999-04-09 WO PCT/US1999/004297 patent/WO1999052896A1/en not_active Ceased
- 1999-04-09 IL IL13867799A patent/IL138677A0/xx unknown
- 1999-04-09 AR ARP990101636A patent/AR015759A1/es unknown
- 1999-04-09 CZ CZ20003672A patent/CZ20003672A3/cs unknown
- 1999-04-09 RU RU2000128033/04A patent/RU2215746C2/ru not_active IP Right Cessation
- 1999-04-09 NZ NZ507292A patent/NZ507292A/en unknown
- 1999-04-09 CN CN99807091A patent/CN1304406A/zh active Pending
- 1999-04-09 EP EP99916119A patent/EP1070060A1/en not_active Withdrawn
- 1999-04-09 KR KR1020007011291A patent/KR20010042614A/ko not_active Ceased
- 1999-04-09 TW TW088105718A patent/TWI247008B/zh active
- 1999-04-09 JP JP2000543454A patent/JP2002511462A/ja active Pending
- 1999-04-09 PL PL99343406A patent/PL343406A1/xx unknown
- 1999-04-09 BR BR9910119-0A patent/BR9910119A/pt not_active IP Right Cessation
- 1999-04-10 MY MYPI99001398A patent/MY133473A/en unknown
-
2000
- 2000-10-09 NO NO20005084A patent/NO20005084L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI247008B (en) | 2006-01-11 |
| NO20005084D0 (no) | 2000-10-09 |
| BR9910119A (pt) | 2001-10-09 |
| KR20010042614A (ko) | 2001-05-25 |
| CN1304406A (zh) | 2001-07-18 |
| EP1070060A1 (en) | 2001-01-24 |
| PL343406A1 (en) | 2001-08-13 |
| IL138677A0 (en) | 2001-10-31 |
| NO20005084L (no) | 2000-11-27 |
| CA2326665A1 (en) | 1999-10-21 |
| RU2215746C2 (ru) | 2003-11-10 |
| AU765294B2 (en) | 2003-09-11 |
| WO1999052896A1 (en) | 1999-10-21 |
| JP2002511462A (ja) | 2002-04-16 |
| AR015759A1 (es) | 2001-05-16 |
| AU3449999A (en) | 1999-11-01 |
| NZ507292A (en) | 2003-12-19 |
| CZ20003672A3 (cs) | 2001-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| ATE203515T1 (de) | Meta-substituierte phenylsulphonamidderivate | |
| IL136044A (en) | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same | |
| GB9914486D0 (en) | Medicaments | |
| DK0889875T3 (da) | Cycloproylalkansyrederivater | |
| YU69902A (sh) | Novi derivati piperazina | |
| DE69831868D1 (en) | Antithrombosemittel | |
| HU9500240D0 (en) | New prolin-amide derivatives and pharmaceutical compositions containing them as active component | |
| DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| DK0894084T3 (da) | Kanelsyrederivater og deres anvendelse som integrinantagonister | |
| BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
| MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| AU2536097A (en) | Para-substituted phenylpropanoic acid derivatives as integrin antagonists | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| ZA945836B (en) | Platelet aggregation inhibitors | |
| GEP20053617B (en) | Bridged Piperazine Derivatives | |
| MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. | |
| ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| IL131216A0 (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| FI970452A0 (fi) | Leukotrieenin biosynteesin estäminen ureajohdannaisten avulla | |
| MX9703610A (es) | Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas. |